Reserved Targets. (i) Exhibit D identifies the list of Targets that are reserved by the Parties as of the Effective Date to be Reserved Targets for the Research Program (as such list is updated from time to time in accordance with this Section 3.4(b)(i), the “Reserved Target List”). During the Substitution Period, the Parties may add additional Targets to or remove Targets from the Reserved Target List as mutually agreed by the Parties; provided that unless the Parties otherwise agree, (a) the Reserved Target List may contain no more than [***] at any given time; and (b) the Reserved Target List may contain no more than four (4) Targets in the aggregate at any given time. Any addition or removal of a Target from the Reserved Target List that is mutually agreed by the Parties will be recorded in the minutes of the JSC and will not require a separate amendment to this Agreement. Notwithstanding the foregoing, [***]. For clarity, (A) any Reserved Target that is removed from the Reserved Target List during the Substitution Period will no longer be a Reserved Target or a Collaboration Target effective upon the date that the Parties mutually agree to remove such Reserved Target, (B) all Reserved Targets that do not become Designated Targets will be released from the Reserved Target List and no longer be Reserved Targets or Collaboration Targets effective upon the earliest of (1) the end of the Substitution Period, (2) the date of its removal from the Reserved Target List, and (3) the expiration or termination of the Research Term, and (C) effective as of the date that the clause (A) or (B) applies with respect to a given Reserved Target, (x) the license grants in Sections 7.1(a) and 7.3 and (y) the exclusivity in Article 11, in each case ((x)-(y)) shall terminate with respect to such Reserved Target.
(ii) During the Substitution Period, the Parties acknowledge and agree that Schrödinger shall be entitled, at its election and at its sole cost and expense, to conduct or, subject to Section 3.12, have conducted by a Third Party under and in furtherance of this Agreement in silico, in vitro and in vivo discovery and research activities (1) to validate any Reserved Target(s), and (2) [***] (collectively, “Permitted Reserved Target Activities”). In the event that Schrödinger elects to conduct any Permitted Reserved Target Activities, then Schrödinger shall provide to BMS (via the JSC) periodic updates regarding the Permitted Reserved Target Activities.
Reserved Targets. Exhibit G identifies the Reserved Targets (as further described in Section 3.3(d) below.
Reserved Targets. During the Collaboration Term Lilly may designate any Target related to a Collaboration Therapeutic Area as a "RESERVED TARGET," [*] Lilly shall provide written notice to Isis identifying each Target that Lilly desires to designate as a Reserved Target. The date upon which Isis receives such notice shall be deemed the "RESERVED TARGET NOTICE DATE." [*]
Reserved Targets. The Parties agree that:
(a) Attached Schedule 3.2.2 sets forth a list of six (6) Targets reserved for AbbVie on an exclusive basis to select, at AbbVie’s sole discretion, as a Target for the second (2nd), third (3rd), or fourth (4th) Program Slots (or as a Substitute Target) (each a “Reserved Target”). The list of Reserved Targets shall not exceed six (6) Targets at any time;
(b) The list of Reserved Targets shall be [***] if, prior to expiration of the Additional Program Slot Period, AbbVie elects [***];
(c) The list of Reserved Targets shall be reduced to [***] if, prior to expiration of the Additional Program Slot Period, AbbVie elects [***]; and
(d) At any time, AbbVie may replace, at AbbVie’s sole discretion, any Reserved Target provided that, (i) such replacement shall not occur more than once per Calendar Year and (ii) such replacement shall follow the nomination process in Section 3.2.6, mutatis mutandis, and the Target Nomination Notice shall identify the to-be-replaced Reserved Target(s).
Reserved Targets. Promptly after the Effective Date, but in no event later than [***] after the Effective Date, the Parties shall enter into an agreement with the initial Gatekeeper that meets the criteria under Section 2.4.1. Dicerna shall promptly thereafter provide such Gatekeeper a list of all of its Blocked Targets, which may be modified from time to time pursuant to Section 2.4.2. During the Research and Collaboration Term, Xxxxx may identify to the Gatekeeper up to the following number of Targets that Xxxxx wishes to reserve for potential selection for further Development pursuant to the Research Program (such Targets individually and collectively referred to as “Reserved Targets”), subject to Section 2.1.3:
(a) up to [***] potential hepatocyte Targets, other than the Initially Named Targets, expected to have applications in the treatment of cardiometabolic indications (“Other Hepatocyte Cardiometabolic Targets”);
(b) up to [***] non-hepatocyte Targets expected to have applications in the treatment of cardiometabolic indications (“Non-Hepatocyte Cardiometabolic Targets”); and
(c) such other non-hepatocyte targets [***] selected by Xxxxx expected to have applications in the treatment of Neurodegeneration or Pain Indications (“Non-Hepatocyte Neurodegeneration/Pain Targets” and, together with the Non-Hepatocyte Cardiometabolic Targets, the “Non-Hepatocyte Targets”). Lilly shall submit its initial list of Reserved Targets within [***] after the Effective Date, and thereafter may, in its discretion, substitute another Target for any Reserved Target provided that at the time of such substitution such substituted Target is not a Blocked Target.
Reserved Targets. The Parties acknowledge that , as of the Effective --------------------- Date, there are certain Targets with respect to which Pharmacopeia may have obligations under its existing agreements with Third Parties, and that Pharmacopeia will not conduct certain research activities with respect to such Targets in connection with the Collaboration (each such Target a "Reserved Target"). SPL shall not knowingly request Pharmacopeia to develop assays with respect to, or screen any Libraries against, such Reserved Targets. * In the event that during the term of the Collaboration Pharmacopeia's Third Party obligations with respect to a given Reserved Target expire, or such Reserved Target otherwise becomes available for unrestricted use in the Collaboration, Pharmacopeia shall promptly notify SPL and such Target shall thereafter cease to be a Reserved Target. It is further __________________ * CONFIDENTIAL TREATMENT REQUESTED understood and agreed that, notwithstanding any other provision of this Agreement, Pharmacopeia shall not be obligated to conduct any activities in performance of the Collaboration that would constitute a breach of any of its obligations to any Third Party.
Reserved Targets. The discovery, research or development of an ASO that is designed to bind to the RNA that encodes any of the Reserved Targets, from the date each such oncology gene target becomes a Reserved Target under Section 3.3.5 until the date such Reserved Target ceases to be a Reserved Target by operation of Section 3.3.6;
Reserved Targets. Ionis may designate up to [***] Targets that Ionis wishes to reserve to be potentially the subject of its Research and Development efforts under this Agreement, and that are not BicycleTx Excluded Targets (“Reserved Targets”) as further described in this Section 2.2.3. The Parties acknowledge and agree that as of the Effective Date, BicycleTx has provided the Interim Gatekeeper with the current list of BicycleTx Excluded Targets, and Ionis has provided the Interim Gatekeeper with its current list of Reserved Targets. During the Term when Oligo Exclusivity applies, [***]. Ionis may not [***] without BicycleTx’s prior written consent. Each Reserved Target shall remain on the Gatekeeper List until [***] directed to such Reserved Target and notifies BicycleTx in writing of the applicable Target. Upon the termination of Oligo Exclusivity, if applicable, all Reserved Targets shall be removed from the Gatekeeper List. The identity of the Reserved Targets shall be the Confidential Information of Ionis. BicycleTx agrees that it will not take any action that would cause a Reserved Target to become BicycleTx Excluded Target.
Reserved Targets. If BioNTech desires to reserve an Available Nominated Target, then BioNTech shall notify both Autolus and the Gatekeeper in writing of the identity of such
Reserved Targets. During the period beginning on the Effective Date and ending on (a) the earliest to occur of [***] in the case of [***], and (b) on the [***], in the case of [***] (each period, with respect to the applicable Reserved Target, the “Reserved Target Period”), Lilly may name a Reserved Target as an Additional Target or Replacement Target, if applicable. During the applicable Reserved Target Period: (x) Precision will provide quarterly updates to Lilly regarding Precision’s development efforts (if any) with respect to each Reserved Target, including updates on clinical trials of compounds directed to such Reserved Targets as data from such trials becomes available; and (y) the Reserved Target shall not be considered an Unavailable Target. If a Reserved Target is not named by Lilly as an Additional Target or Replacement Target during the applicable Reserved Target Period, then from and after the expiration of such Reserved Target Period, such Reserved Target will be deemed an Unavailable Target and not a Reserved Target. Notwithstanding the foregoing, in the case of [***], if the Reserved Target Period expires on the [***] of the Effective Date pursuant to Section 3.5(a)(i), [***] shall cease to be a Reserved Target upon expiration of the Reserved Target Period but shall not be deemed to be an Unavailable Target as a result of such expiration.
